secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inmune Bio, Inc. (INMB)
CIK:        0001711754
Form:       8-K
Filed at:   2025-10-30T23:59:59+00:00
Accession:  0001213900-25-104154
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INmune Bio Q3 net loss $6.5M; appoints new CEO, CFO; INKmune trial meets primary endpoint
--------------------------------------------------------------------------------

- Net loss narrowed to $6.5M from $12.1M YoY; R&D spend cut to $4.9M; cash $27.7M.
- David Moss appointed President & CEO replacing Dr. RJ Tesi; Cory Ellspermann named CFO.
- XPro1595 Phase 2 MINDFuL results manuscript submitted; End-of-Phase 2 meeting with FDA expected Q1 2026.
- INKmune CARE-PC trial met primary endpoint and 2 of 3 secondary endpoints; trial closed to recruitment.
- CORDStrom commercial pilot runs complete; MAA submission on track for mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/0001213900-25-104154-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711754/000121390025104154/ea0263196-8k_inmune.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-104154

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer